This study reveals how signals from the suprachiasmatic nucleus coordinate the metabolic flexibility of BAT, through a adrenergic receptor ADRB3-S100B signaling axis, thereby identifying a new therapeutic target for metabolic disorders. This evidence concerns the gene ADRB3 and metabolic disease.